Albiglutide
Previously FDA-approved weekly GLP-1 (a gut hormone signal for fullness and blood-sugar handling) medicine (Tanzeum); market discontinued.
What it's for
Previously FDA-approved weekly GLP-1 (a gut hormone signal for fullness and blood-sugar handling) medicine (Tanzeum); market discontinued.
What it's for
Albiglutide is a GLP-1 (a gut hormone signal for fullness and blood-sugar handling) dimer fused to albumin for once-weekly dosing.
What it does for the body
It was approved to improve blood-sugar control in type 2 diabetes. The manufacturer discontinued U.S. commercial supply for business reasons; that is not the same as an FDA safety withdrawal narrative alone.
What it targets
GLP-1 (a gut hormone signal for fullness and blood-sugar handling) receptors (lock-and-key landing spots on cells) activating its target pathway with extended how long it stays active in the body via albumin fusion. Think of it like turning up a dimmer switch on the body's natural "I'm full / handle sugar after meals" signal.
Research context
Bottom line for readers: Albiglutide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Hormones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Albiglutide — FDA.gov search
- ClinicalTrials.gov search: Albiglutide — U.S. clinical trials registry
- Drugs@FDA search: Albiglutide — FDA drug database (if approved)
- PubMed search: Albiglutide — NCBI PubMed
- PubMed Central search: Albiglutide — NCBI PMC